Clinical Trial Update: A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy [Phase 3]

View source ↗

Summary

Phase 3 study comparing Daratumumab-VELCADE-Lenalidomide-Dexamethasone (D-VRd) vs VELCADE-Lenalidomide-Dexamethasone (VRd) in untreated multiple myeloma patient…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• Daratumumab (daratumumab)
• Lenalidomide (lenalidomide)
• Velcade (bortezomib)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Multiple Myeloma | Phase 3 | Status: COMPLETED | Results posted: 2026-04-08